Cancer Drugs With Apoptotic Targets In DevelopmentBiophoenix LimitedJuly 1, 2010 32 Pages - SKU: BPH2737529 |
| Cancer drugs with apoptotic targets in development, updated July 2010, provides key information on 138 targeted apoptotic drugs in anticancer development by a total of 104 companies. These drugs are directed at the products of one or more of over 40 genes involved in apoptosis (programmed cell death).
Most current cancer therapies, including chemotherapeutic agents, work by inducing apoptosis in cancer cells. However, many cancer cells are resistant or develop resistance to these agents. A promising new direction for drug development involves approaches designed to overcome treatment resistance due to over-expression of anti-apoptotic genes or downregulation of pro-apoptotic genes. Apoptotic drugs in anticancer development were identified using a wide variety of sources, including Biophoenix's proprietary company database, various online databases, the scientific literature, academic and company websites, company press releases, web-based news searches, industry newsletters, and conference proceedings. Apoptotic anticancer drugs are characterized in terms of their target(s), development status, originator company/licensee, therapy type, mode of action, and indication. |
Related Markets
- Biotechnology
- Research & Development
- Pharmaceuticals
- Research & Development
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
